Opening the door to innovation

descriptionPublicationkeyboard_double_arrow_right Article 24 Apr 2014 English Publisher:Informa UK LimitedJournal:mAbs, volume 6, pages 812-819 (issn: 1942-0870, eissn: 1942-0862,

Copyright policy )

Authors: Schuurman, Janine; Graus, Yvo F; Labrijn, Aran F; Ruuls, Sigrid R; Parren, Paul WHI;

doi: 10.4161/mabs.29004

pmid: 24784437

pmc: PMC4171017

Opening the door to innovation

- Summary
- Subjects
- Metrics

Abstract

Open innovation is the new buzz, with initiatives popping up left and right. Here, we give a personal perspective on a very successful, knowledge-driven innovation initiated in an academia- industry alliance, which culminated in technology platforms that enable the generation of therapeutic antibodies with novel properties. To start, we provide a general background on open innovation in the drug development field.

Related Organizations

Genmab (United States)
United States

Keywords

Drug Design, Perspective, Animals, Antibodies, Monoclonal, Humans, Drug Approval

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	13
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%